BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 16292596)

  • 1. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein.
    James CM; Abdad MY; Mansfield JP; Jacobsen HK; Vind AR; Stumbles PA; Bartlett EJ
    Vaccine; 2007 Feb; 25(10):1856-67. PubMed ID: 17240000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.
    Ohba K; Yoshida S; Zahidunnabi Dewan M; Shimura H; Sakamaki N; Takeshita F; Yamamoto N; Okuda K
    Vaccine; 2007 May; 25(21):4291-300. PubMed ID: 17403560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus.
    Saha S; Yoshida S; Ohba K; Matsui K; Matsuda T; Takeshita F; Umeda K; Tamura Y; Okuda K; Klinman D; Xin KQ; Okuda K
    Virology; 2006 Oct; 354(1):48-57. PubMed ID: 16945400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
    Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L
    Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
    Fu TM; Guan L; Friedman A; Schofield TL; Ulmer JB; Liu MA; Donnelly JJ
    J Immunol; 1999 Apr; 162(7):4163-70. PubMed ID: 10201942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.
    Price GE; Soboleski MR; Lo CY; Misplon JA; Pappas C; Houser KV; Tumpey TM; Epstein SL
    Vaccine; 2009 Nov; 27(47):6512-21. PubMed ID: 19729082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Breathnach CC; Clark HJ; Clark RC; Olsen CW; Townsend HG; Lunn DP
    Vaccine; 2006 Feb; 24(8):1180-90. PubMed ID: 16194586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.
    Zanvit P; Havlícková M; Tácner J; Novotná O; Jirkovská M; Cechová D; Julák J; Sterzl I; Prokesová L
    Immunol Lett; 2008 Jan; 115(2):144-52. PubMed ID: 18160106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.
    Huang B; Wang W; Li R; Wang X; Jiang T; Qi X; Gao Y; Tan W; Ruan L
    Virol J; 2012 Dec; 9():322. PubMed ID: 23272943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A live bivalent influenza vaccine based on a H9N2 virus strain.
    Wu R; Guan Y; Yang Z; Chen J; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Vaccine; 2010 Jan; 28(3):673-80. PubMed ID: 19892041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.